17 Jan Keywords: bicarbonate, dichloroacetate, glioma, hyperpolarized 13C therapies and metabolic modulation, with improved ef- fectiveness have. Metabolic Modulation of Glioblastoma with Dichloroacetate (DCA) can reverse this cancer-specific metabolic and mitochondrial remodeling in glioblastoma. Metabolic modulation of glioblastoma with dichloroacetate. Authors: ED. Michelakis, G Sutendra, P Dromparis, L. C. Webster, A Haromy, E Niven, C. Maguire.
|Published (Last):||14 October 2018|
|PDF File Size:||20.80 Mb|
|ePub File Size:||6.74 Mb|
|Price:||Free* [*Free Regsitration Required]|
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology Gopinath SutendraEvangelos D Michelakis Front. Solid tumors, including the aggressive primary brain divhloroacetate glioblastoma multiforme, develop resistance to cell death, in part as a result of a switch from mitochondrial oxidative phosphorylation to cytoplasmic glycolysis.
Indications of clinical efficacy were present at a dose that did not cause peripheral neuropathy and at serum concentrations of DCA sufficient to inhibit the target enzyme of DCA, pyruvate dehydrogenase kinase II, which was highly expressed in all glioblastomas. Log in to view the full text via AAAS login. Showing of 60 references.
More options Purchase digital access to this article Download and print this article for your personal scholarly, research, and educational use.
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather metzbolic as a single agent in advanced non-small cell lung cancer. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Register for free to read this article.
This information is designed for health professionals. Cancer Chemother Pharmacol ; Log in through your institution Log in via OpenAthens. DCA depolarized mitochondria, increased mitochondrial reactive oxygen species, and induced apoptosis in GBM cells, as well as in putative GBM stem cells, both in vitro and in vivo. The dose-limiting toxicity was a dose-dependent, reversible peripheral neuropathy, and there was no hematologic, hepatic, renal, or cardiac toxicity. Ronen Cancer research The pharmacology of dichloroacetate.
J Dichlproacetate Pharmacol ; Adv Drug Deliv Rev ; VolumeArticle ID4 pages. Garon et al conducted a phase I trial to evaluate the efficacy and safety of DCA in the treatment of advanced solid tumors.
The dose-limiting toxicity was a dose-dependent, reversible peripheral neuropathy, and there was no hematologic, hepatic, renal, or cardiac toxicity.
Science 9 November VolIssue Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase, shifts metabolism away from aerobic glycolysis in glioblastoma tumor cells and may have clinical efficacy in patients. Solid tumors, including the aggressive primary brain cancer glioblastoma multiforme, develop resistance to cell death, in part as a result of a switch from mitochondrial oxidative phosphorylation to cytoplasmic glycolysis.
Metabolic modulation of cancer: Biotransformation, Toxicology and Pharmacogenomics of Dichloroacetate.
Metabolic modulation of glioblastoma with dichloroacetate.
Freshly isolated glioblastomas from 49 patients showed mitochondrial hyperpolarization, which was rapidly reversed by DCA. Pharmacogenetic considerations with dichloroacetate dosing. Metabolic modulation of gliobpastoma with dichloroacetate. Topics Discussed in This Paper.
Metabolic modulation of glioblastoma with dichloroacetate. – Semantic Scholar
Based on this phase I trial an effect of DCA in the treatment of advanced and treatment refractory solid tumors can neither be supported nor negated Based on these results, a limited effect of DCA on glioblastoma or brain metastases could be hypothesized Scientific Integrity Whose science?
Environmental Policy Why conservatives abandoned conservation. Food and Drug Administration. We pf whether the small-molecule and orphan drug glioblastlma DCA can reverse this cancer-specific metabolic and mitochondrial remodeling in glioblastoma. Petruk, Metabolic modulation of glioblastoma with dichloroacetate.
Treatment was continued to a maximum of 28 days, until disease progression or unacceptable toxicity occurred. Metabolic Modulation of Glioblastoma with Dichloroacetate.
Pharmacokinetics, metabolism and toxicology of dichloroacetate. Citations Publications citing this paper. LippardMitaplatina potent fusion of cisplatin and the orphan drug dichloroacetate.